Acarix deltar på Aktiedagen den 15 oktober i Stockholm


Acarix deltar på Aktiedagen den 15 oktober på Operaterasen, Karl XII:s torg, Stockholm

VD Per Persson, presenterar klockan 16.00. Aktiedagen anordnas av Aktiespararna.

Via denna länk kan du anmäla dig direkt:

Om Du inte har möjlighet att närvara på plats kan Du alltid följa presentationerna via webben.

Aktiedagen sänds live på och on demand på


About Acarix
Acarix is a Swedish medical device company that innovates solutions for rapid AI-based rule out of Coronary Artery Disease (CAD). The CE approved and FDA DeNovo cleared Acarix CADScor®System is intended for patients experiencing chest pain with suspected CAD and designed to help reduce millions of unnecessary, invasive and costly diagnostic procedures. The CADScor system calculates a patient-specific CAD-score non-invasively in less than10 minutes and can help rule out more than one third of patients with at least 96% certainty of not being sick (in a population with approx. 10% CAD prevalence). Acarix is listed on the Nasdaq First North Premier Growth Market (ticker: ACARIX). Redeye AB (+46 (0)8 121 576 90, is Certified Advisor of Acarix.

For more information, please visit